pharmaphorum

FEBRUARY 19, 2021

Rigel’s clinical-stage R552 is the main asset in the deal – which also includes $835 million in development, regulatory, and commercial milestones – but Lilly has also taken rights to preclinical-stage follow-ups that can cross into the brain and may have potential in central nervous system disorders.

Compounding 52

Compounding Immunization Immunity Drug Development 52

Pharmaceutical Technology

FEBRUARY 13, 2023

This makes early R&D less risky, as many lead compounds are discontinued due to inadequate pharmacokinetic profiles and require excessively high dosages to be pharmaceutically active. However, on-target adverse events are also common with BTKis as they inhibit B-cell immune responses, which can result in serious infections.

Dosage 59

Dosage Chemotherapy Compounding Immunization 59

Pharmaceutical Technology

JUNE 21, 2023

Life sciences venture capital firm Flagship Pioneering has unveiled Empress Therapeutics, a small molecule drug development startup. This will support development of its proprietary Chemilogics platform and drug discovery pipeline. So far, Empress claims to have generated 15 drug leads across multiple indications.

Compounding 52

Compounding Communication Immunization Immunity 52

PharmaTech

JUNE 9, 2025

Nanoparticles have attracted particular attention, including those based on lipids, polymers (natural and synthetic), lipid-polymer hybrids, dendrimers, inorganic materials (metals, magnetic compounds, carbon nanotubes, silica-based systems, etc.).

Dosage 52

Dosage Drug Development Immunization Immunity 52

European Pharmaceutical Review

FEBRUARY 13, 2025

As drug developers consider oligos potential, they often explore innovations in chemical modifications and delivery systems to ensure these therapies reach their full potential. Finally, oligo metabolites often share similar structures and molecular weights with parent compounds, leading to potential interference during analysis.

Compounding 52

Compounding Immunization Immunity Drug Development 52

PharmaShots

MARCH 14, 2023

The article focuses on challenges faced in drug development, government incentive programs, grants, and various therapies used to diagnose or treat rare diseases. How challenging is the drug development plan Drug development plans for rare diseases can be circuitous, resulting in fewer participation from companies.

Drug Development 40

Drug Development Immunization Immunity Compounding 40

Express Pharma

APRIL 4, 2024

Advantages of lipids and essential factors in selection Lipid-based formulations play a pivotal role in drug discovery and delivery, enhancing bioavailability by controlling therapeutic compounds’ solubility, permeability, absorption, distribution, and metabolism.

Vaccines 98

Vaccines Compounding Immunization Immunity 98

PharmaTech

JUNE 12, 2025

By combining assets, both companies aim to streamline mRNA drug development pipelines and manufacturing workflows, potentially reducing timelines for delivering clinical-stage therapies to patients. billion (1). billion (1). The integrated platform will be positioned to support mRNA applications from discovery to commercialization.

Dosage 52

Dosage Drug Development Vaccines Packaging 52

PharmaTech

JUNE 10, 2025

The global biopharma industry is expected to increase at a compound annual growth rate of 8.97% from 2025 to 2030; this growth is suspected to result from a demand for targeted therapies, new alliances, and increased innovation (1).

Dosage 52

Dosage Drug Development Vaccines Compounding 52

pharmaphorum

AUGUST 27, 2020

Regulatory pressures, lengthy drug development times, and the fact that drug prices have become politicised have raised risks and cut revenue projections, leading to the biotech sector falling out of fashion. The first is that the development of vaccines is utilising cutting edge technologies.

Vaccines 122

Vaccines Drug Pricing Compounding Immunization 122

PharmaTech

JUNE 12, 2025

s CDC Vaccine Committee Overhaul for the Pharmaceutical Industry Christopher Cole June 10th 2025 Article The dismissal of all 17 members of the Advisory Committee on Immunization Practices has far-reaching impacts for the industry and beyond. Implications of RFK Jr.’s Implications of RFK Jr.’s

Dosage 59

Dosage Drug Development Labelling Compounding 59

European Pharmaceutical Review

MARCH 4, 2024

Indeed, in 2022, biologics constituted 40 percent of all US Food and Drug Administration (FDA) approved drugs, projecting a compound annual growth rate (CAGR) of 9.5 Anna has a medical degree and a postgraduate degree in healthcare management and is an expert in all stages of drug development. percent through 2027.

Vaccines 98

Vaccines Immunization Immunity Compounding 98

National Association of Boards of Pharmacy

APRIL 23, 2025

Foundational Knowledge for Pharmacy Practice Testing your pharmaceutical science knowledge, including compounding, drug development, and more. 25% (50 questions) 2. 25% (50 questions) 3.

Pharmacy Management 40

Pharmacy Management Documentation Compounding Immunization 40